Bond.az White LogoBond.az Black Logo

ThinkEquity Initiates Atlas with Buy

ThinkEquity initiates Atlas Technical Consultants with a Buy rating and $15 target. The firm highlights the value of the Brazil critical-minerals option.

Robert Moore
ByRobert Moore- Senior Editor
|
0

ThinkEquity initiated coverage on Atlas Technical Consultants Inc. (NASDAQ:ATCX) with a Buy rating and a $15.00 price target.

The firm bases its rating on an asymmetry between current enterprise value and three probability-adjusted technical paths: Alto Paranaíba rare earths/titanium, Malacacheta graphite, and Rio Piracicaba iron ore cash offset. At a $4.34 reference price and roughly 5.0 million basic shares, market cap is about $21.7 million. The stock trades at $4.44, near its 52-week low of $4.28, reflecting a sharp decline in investor sentiment.

The January offering provided $9.7 million net after Atlas sold 1.38 million shares at $8.00. That funding supports the next exploration cycle but does not make assets development-ready or remove future capital needs if drilling, metallurgy, and option exercise advance simultaneously.

Atlas reported 2025 revenue of $92,491 vs. $667,131 in 2024, gross loss of $59,431 vs. gross profit of $265,694, and net loss of $5.420 million vs. $1.713 million. The gross profit margin stands at negative 64%, highlighting operational challenges.

ThinkEquity values the equity through a risked asset-option sum-of-the-parts approach. For deeper analysis, Bond.az offers 15 additional tips and comprehensive financial health metrics.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
731

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
ThinkEquity Initiates Atlas with Buy | Bond.az